Calithera Biosciences (CALA) Misses Q4 EPS by 9c

Calithera Biosciences (NASDAQ: CALA) reported Q4 EPS of ($0.31), $0.09 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $7.25 million versus the consensus estimate of $5.46 million.

For earnings history and earnings-related data on Calithera Biosciences (CALA) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• ASML Holding NV (ASML:NA) (ASML) PT Raised to EUR2,000 at Goldman Sachs
• Innovex closes $95M acquisition of TCO Group AS